WCG seeks strategic partnerships in order to distribute innovative new products in developing markets.
Amphora has been submitted to the United States Food and Drug Administration (FDA) for approval as a non-hormonal, contraceptive vaginal gel. The application is based on the results of a large, multicenter, open-label, randomized, phase III trial that examined the repeated use of Amphora gel compared to a vaginal gel containing Nonoxynol-9 as the primary method of contraception over seven cycles of use. Amphora works by restoring the vaginal pH levels to those consistent with a healthy vaginal environment. A healthy vaginal environment acts against both sperm, as well as, viral and bacterial pathogens. In addition to a regulatory filing for approval as a contraceptive, Amphora is being investigated for microbicidal properties to develop a potential multipurpose prevention technology.
Innovative Contraceptive Vaginal Ring
The Population Council and WomanCare Global (WCG) have partnered for an exclusive worldwide licensing agreement for WCG to make the Council’s investigational Nestorone®/Ethinyl Estradiol contraceptive vaginal ring available in the developed and developing markets. During clinical trials, the NES/EE ring has shown the potential to meet the needs of those women looking for an effective, long-acting method of contraception that they can fully control. The clinical trials were designed to assess the safety and effectiveness of the ring including the utilization for up to one year by the patient.